{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:50:35Z","timestamp":1793242235841,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.therap.2020.06.019","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T18:35:07Z","timestamp":1594319707000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0737-5097","authenticated-orcid":false,"given":"Arun","family":"Koyyada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.06.019_bib0420","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/MOG.0b013e328358d5b9","article-title":"Proton pump inhibitors: potential adverse effects","volume":"28","author":"Abraham","year":"2012","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.therap.2020.06.019_bib0425","first-page":"467","article-title":"Omeprazole and H2 receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis","volume":"7","author":"Eriksson","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.therap.2020.06.019_bib0430","first-page":"728","article-title":"Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.therap.2020.06.019_bib0435","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease","volume":"100","author":"DeVault","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.therap.2020.06.019_bib0440","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10620-010-1560-3","article-title":"Adverse effects of long-term proton pump inhibitor therapy","volume":"56","author":"Sheen","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.therap.2020.06.019_bib0445","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1056\/NEJMsa0803410","article-title":"Cardiovascular outcomes after a change in prescription policy for clopidogrel","volume":"359","author":"Melo","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.06.019_bib0450","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1157\/13095825","article-title":"Safety of proton pump inhibitors","volume":"127","author":"Esplugues","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.therap.2020.06.019_bib0455","first-page":"1934","article-title":"Side effects of proton pump inhibitors (PPIs)","volume":"3","author":"Maffei","year":"2007","journal-title":"Rev Med Suisse"},{"issue":"Suppl. 2","key":"10.1016\/j.therap.2020.06.019_bib0460","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: the clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.therap.2020.06.019_bib0465","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2036.2004.01893.x","article-title":"Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers","volume":"19","author":"Galmiche","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.therap.2020.06.019_bib0470","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.therap.2020.06.019_bib0475","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1592\/phco.23.13.68S.31931","article-title":"Physiology of the parietal cell and therapeutic implications","volume":"23","author":"Sachs","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.therap.2020.06.019_bib0480","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.therap.2020.06.019_bib0485","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1021\/ja049607w","article-title":"Chemistry of covalent inhibition of the gastric (H+,K+)-ATPase by proton pump inhibitors","volume":"126","author":"Shin","year":"2004","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.therap.2020.06.019_bib0490","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/bi00060a028","article-title":"Membrane topology and omeprazole labeling of the gastric H+,K+-adenosinetriphosphatase","volume":"32","author":"Besancon","year":"1993","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.therap.2020.06.019_bib0495","first-page":"122","article-title":"Neurological disorders in vitamin B12 deficiency","volume":"91","author":"Pavlov","year":"2019","journal-title":"Ter Arkh"},{"key":"10.1016\/j.therap.2020.06.019_bib0500","first-page":"303","article-title":"Human gastric intrinsic factor expression is not restricted to parietal cells","volume":"189","author":"Howard","year":"1996","journal-title":"J Anat"},{"issue":"2","key":"10.1016\/j.therap.2020.06.019_bib0505","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocpiqo.2019.03.002","article-title":"The many faces of cobalamin (vitamin B12) deficiency","volume":"3","author":"Wolffenbuttel","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.therap.2020.06.019_bib0510","doi-asserted-by":"crossref","first-page":"211","DOI":"10.7326\/0003-4819-120-3-199402010-00006","article-title":"Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12)","volume":"120","author":"Marcuard","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2020.06.019_bib0515","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/01639360903574734","article-title":"Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial?","volume":"29","author":"Rozgony","year":"2010","journal-title":"J Nutr Elder"},{"key":"10.1016\/j.therap.2020.06.019_bib0520","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jamda.2007.10.004","article-title":"Do acid-lowering agents affect vitamin B12 status in older adults?","volume":"9","author":"Dharmarajan","year":"2008","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"10.1016\/j.therap.2020.06.019_bib0525","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3889\/oamjms.2018.142","article-title":"Proton pump inhibitors intake and iron and vitamin B12 status: a prospective comparative study with a follow-up of 12 months","volume":"6","author":"Qorraj-Bytyqi","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.therap.2020.06.019_bib0530","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2036.2008.03601.x","article-title":"Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals","volume":"27","author":"den Elzen","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2020.06.019_bib0535","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0016-5085(89)90071-1","article-title":"Ascorbic acid in the human stomach","volume":"97","author":"Sobala","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.therap.2020.06.019_bib0540","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0891-5849(94)90019-1","article-title":"The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective","volume":"17","author":"Winkler","year":"1994","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.therap.2020.06.019_bib0545","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0016-5085(99)70064-8","article-title":"Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice","volume":"116","author":"Mowat","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.therap.2020.06.019_bib0550","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2036.2005.02568.x","article-title":"Proton pump inhibitors reduce the bioavailability of dietary vitamin C","volume":"22","author":"Henry","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.therap.2020.06.019_bib0555","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5527\/wjn.v1.i6.151","article-title":"Proton pump inhibitor-induced hypomagnesemia: a new challenge","volume":"1","author":"Florentin","year":"2012","journal-title":"World J Nephrol"},{"key":"10.1016\/j.therap.2020.06.019_bib0560","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/MOG.0b013e32833ff5d6","article-title":"Proton pump inhibitors and severe hypomagnesaemia","volume":"27","author":"Cundy","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"issue":"6","key":"10.1016\/j.therap.2020.06.019_bib0565","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/qjmed\/hcq021","article-title":"Hypomagnesaemia due to proton pump inhibitor therapy: a clinical case series","volume":"103","author":"Mackay","year":"2010","journal-title":"QJM"},{"issue":"37","key":"10.1016\/j.therap.2020.06.019_bib0570","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.3748\/wjg.v23.i37.6907","article-title":"Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication","volume":"23","author":"Semb","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.therap.2020.06.019_bib0575","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tifs.2020.02.021","article-title":"Iron deficiency anemia: a comprehensive review on iron absorption, bioavailability and emerging food fortification approaches","volume":"99","author":"Shubham","year":"2020","journal-title":"Trends Food Sci Technol"},{"key":"10.1016\/j.therap.2020.06.019_bib0580","doi-asserted-by":"crossref","first-page":"108976","DOI":"10.1016\/j.foodres.2020.108976","article-title":"Food protein-derived iron-chelating peptides: the binding mode and promotive effects of iron bioavailability","volume":"131","author":"Wu","year":"2020","journal-title":"Food Res Int"},{"key":"10.1016\/j.therap.2020.06.019_bib0585","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.toxlet.2019.10.016","article-title":"Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway","volume":"318","author":"Hamano","year":"2020","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.therap.2020.06.019_bib0590","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1136\/gut.2006.108613","article-title":"Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis","volume":"56","author":"Hutchinson","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.therap.2020.06.019_bib0595","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/01.SMJ.0000110405.63179.69","article-title":"Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia","volume":"97","author":"Sharma","year":"2004","journal-title":"South Med J"},{"issue":"7\u20138","key":"10.1016\/j.therap.2020.06.019_bib0600","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/08880018.2016.1247392","article-title":"Proton pump inhibitors use suppresses iron absorption in congenital dyserythropoietic anemia","volume":"33","author":"Shalev","year":"2016","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"10.1016\/j.therap.2020.06.019_bib0605","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2169\/internalmedicine.9554-17","article-title":"Iron deficiency anemia due to the long-term use of a proton pump inhibitor","volume":"57","author":"Imai","year":"2018","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.therap.2020.06.019_bib0610","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4274\/tjh.2013.0042","article-title":"Effects of omeprazole on iron absorption: preliminary study","volume":"30","author":"Tempel","year":"2013","journal-title":"Turk J Haematol"},{"issue":"6","key":"10.1016\/j.therap.2020.06.019_bib0615","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11894-012-0290-4","article-title":"Chronic proton pump inhibitor therapy and calcium metabolism","volume":"14","author":"Yang","year":"2012","journal-title":"Curr Gastroenterol Rep"},{"issue":"9","key":"10.1016\/j.therap.2020.06.019_bib0620","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJM198708273170903","article-title":"Gastrointestinal absorption of calcium from milk and calcium salts","volume":"317","author":"Sheikh","year":"1987","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.therap.2020.06.019_bib0625","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/gut.26.3.252","article-title":"Regulation of vitamin D and calcium metabolism after gastrectomy","volume":"26","author":"Nilas","year":"1985","journal-title":"Gut"},{"key":"10.1016\/j.therap.2020.06.019_bib0630","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.amjmed.2005.02.007","article-title":"Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial","volume":"118","author":"O\u2019Connell","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2020.06.019_bib0635","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000003178","article-title":"Proton pump inhibitors, but not H2 receptor antagonists, are associated with incident fractures among kidney transplant recipients","author":"Lyu","year":"2020","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.therap.2020.06.019_bib0640","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamapediatrics.2020.0007","article-title":"Association between proton pump inhibitor use and risk of fracture in children","volume":"174","author":"Wang","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.therap.2020.06.019_bib0645","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis related fractures","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ"},{"issue":"7","key":"10.1016\/j.therap.2020.06.019_bib0650","first-page":"853","article-title":"Use of proton pump inhibitors during pregnancy and breastfeeding","volume":"52","author":"Nava-Ocampo","year":"2006","journal-title":"Can Fam Physician"},{"issue":"11","key":"10.1016\/j.therap.2020.06.019_bib0655","first-page":"763","article-title":"Treatment of gastroesophageal reflux disease during pregnancy","volume":"8","author":"Gerson","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"10.1016\/j.therap.2020.06.019_bib0660","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/apt.15611","article-title":"Review article: the management of heartburn during pregnancy and lactation","volume":"51","author":"Th\u00e9lin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2020.06.019_bib0665","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1023\/A:1015863018105","article-title":"Use of proton pump inhibitors during pregnancy and rates of major malformations. A meta-analysis","volume":"47","author":"Nikfar","year":"2002","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.therap.2020.06.019_bib0670","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1471-0528.1998.tb10233.x","article-title":"Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole","volume":"105","author":"Kallen","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.therap.2020.06.019_bib0675","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/apt.15610","article-title":"Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy","volume":"51","author":"Li","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2020.06.019_bib0680","first-page":"825","article-title":"Excretion of pantoprazole in human breast milk","volume":"49","author":"Plante","year":"2004","journal-title":"J Reprod Med"},{"key":"10.1016\/j.therap.2020.06.019_bib0685","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2036.2005.02306.x","article-title":"The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study","volume":"21","author":"Diav-Citrin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2020.06.019_bib0690","article-title":"Role of hypothyroidism and associated pathways in pregnancy and infertility: clinical insights","author":"Koyyada","year":"2020","journal-title":"Tzu Chi Med J"},{"key":"10.1016\/j.therap.2020.06.019_bib0695","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.3390\/ijms20205128","article-title":"Insights into effects\/risks of chronic hypergastrinemia and lifelong PPI treatment in man based on studies of patients with Zollinger\u2013Ellison syndrome","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.therap.2020.06.019_bib0700","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/hupa.2000.7637","article-title":"Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment","volume":"31","author":"Cats","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.therap.2020.06.019_bib0705","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1365-2036.2006.03127.x","article-title":"Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy","volume":"24","author":"Jalving","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2020.06.019_bib0710","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2036.2006.02792.x","article-title":"Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial","volume":"23","author":"Lundell","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.therap.2020.06.019_bib0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36159\/jgs.v2i1.17","article-title":"Long-term proton pump inhibitor use and the incidence of gastric cancer: a systematic review and meta-analysis","volume":"2","author":"Lin","year":"2020","journal-title":"J Gastric Surg"},{"key":"10.1016\/j.therap.2020.06.019_bib0720","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0016-5085(00)70135-1","article-title":"Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa","volume":"118","author":"Klinkenberg-Knol","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.therap.2020.06.019_bib0725","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/ijms21020662","article-title":"Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids\u00a0\u2013\u00a0what is the relationship?","volume":"21","author":"McCarthy","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.therap.2020.06.019_bib0730","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.therap.2020.06.019_bib0735","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.14267","article-title":"A multicentre prospective study evaluating the impact of proton pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations","author":"Blanco Dorado","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"10.1016\/j.therap.2020.06.019_bib0740","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.therap.2020.06.019_bib0745","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.therap.2020.06.019_bib0750","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40256-016-0160-9","article-title":"How may proton pump inhibitors impair cardiovascular health?","volume":"16","author":"Sukhovershin","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"10.1016\/j.therap.2020.06.019_bib0755","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2036.2010.04485.x","article-title":"Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors","volume":"33","author":"Valkhoff","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2020.06.019_bib0760","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fphys.2018.01550","article-title":"PPIs are not responsible for elevating cardiovascular risk in patients on clopidogrel\u00a0\u2013\u00a0a systematic review and meta-analysis","volume":"9","author":"Demcs\u00e1k","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.therap.2020.06.019_bib0765","first-page":"100317","article-title":"Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"23","author":"Pang","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"8","key":"10.1016\/j.therap.2020.06.019_bib0770","first-page":"939","article-title":"Clopidogrel-proton pump inhibitor drug\u2013drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis","volume":"22","author":"Serbin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.therap.2020.06.019_bib0775","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00002018-200326020-00005","article-title":"The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11,541 patients in England","volume":"26","author":"Wilton","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2020.06.019_bib0780","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2125.2000.00262.x","article-title":"The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies","volume":"50","author":"Martin","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.06.019_bib0785","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.14983","article-title":"Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: a 15-year hospital cohort study using a common data model","author":"Seo","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.therap.2020.06.019_bib0790","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1017\/S095026880700996X","article-title":"Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases","volume":"136","author":"Doorduyn","year":"2008","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.therap.2020.06.019_bib0795","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2007.09.010","article-title":"Use of acid-suppressing drugs and the risk of bacterial gastroenteritis","volume":"5","author":"Garcia Rodriguez","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.therap.2020.06.019_bib0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.05.027","article-title":"Incidence, risk factors, and health service burden of sequelae of campylobacter and non-typhoidal salmonella infections in England, 2000\u20132015: a retrospective cohort study using linked electronic health records","author":"Esan","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.therap.2020.06.019_bib0805","first-page":"149","article-title":"A study on the relation between proton pump inhibitor and gastric giardiasis","volume":"28","author":"Kader","year":"1998","journal-title":"J Egypt Soc Parasitol"},{"key":"10.1016\/j.therap.2020.06.019_bib0810","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/BF02349646","article-title":"Proton pump inhibition and gastric giardiasis: a causal or casual association?","volume":"30","author":"Reynaert","year":"1995","journal-title":"J Gastroenterol"},{"issue":"5","key":"10.1016\/j.therap.2020.06.019_bib0815","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/intqhc\/mzaa041","article-title":"Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia","volume":"32","author":"Nguyen","year":"2020","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.therap.2020.06.019_bib0820","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40266-019-00704-6","article-title":"Proton pump inhibitors and infection-related hospitalizations among residents of long-term care facilities: a case control study","volume":"36","author":"Wang","year":"2019","journal-title":"Drugs Aging"},{"issue":"12","key":"10.1016\/j.therap.2020.06.019_bib0825","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/nep.12330","article-title":"Proton pump inhibitor use is associated with lower urinary magnesium excretion","volume":"19","author":"William","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.therap.2020.06.019_bib0830","doi-asserted-by":"crossref","first-page":"012017","DOI":"10.1088\/1755-1315\/293\/1\/012017","article-title":"Long-term proton pump inhibitors induces recurrent urinary tract infections: a case study","volume":"239","author":"Cokro","year":"2019","journal-title":"IOP Conf Ser Earth Environ Sci"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572030127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572030127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:27Z","timestamp":1758567207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059572030127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S004059572030127X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.06.019","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}